Ostarine
- русский язык имя
- английское имяOstarine
- CAS №841205-47-8
- CBNumberCB02514763
- ФормулаC19H14F3N3O3
- мольный вес389.33
- EINECS803-892-7
- номер MDLMFCD16877675
- файл Mol841205-47-8.mol
химическое свойство
| Температура кипения | 632.3±55.0 °C(Predicted) |
| плотность | 1.41±0.1 g/cm3(Predicted) |
| температура хранения | Store at -20°C |
| растворимость | DMSO:70.0(Max Conc. mg/mL);179.8(Max Conc. mM) |
| форма | Solid |
| пка | 12.13±0.29(Predicted) |
| цвет | White to off-white |
| InChI | InChI=1S/C19H14F3N3O3/c1-18(27,11-28-15-6-2-12(9-23)3-7-15)17(26)25-14-5-4-13(10-24)16(8-14)19(20,21)22/h2-8,27H,11H2,1H3,(H,25,26)/t18-/m0/s1 |
| ИнЧИКей | JNGVJMBLXIUVRD-SFHVURJKSA-N |
| SMILES | C(NC1=CC=C(C#N)C(C(F)(F)F)=C1)(=O)[C@](O)(C)COC1=CC=C(C#N)C=C1 |
| FDA UNII | O3571H3R8N |
| Словарь наркотиков NCI | enobosarm |
Ostarine химические свойства, назначение, производство
Использование
Ostarine is nonsteroidal selective androgen receptor modulator (SARM) used in the treatment of osteoporosis and muscle wasting in animal models. A potential compound for the treatment of hypoactive sexual desire disorder.Origin
Ostarine is an orally bioavailable, nonsteroidal SARM that was developed by Gtx, Inc. in the late 1990s primarily for the treatment of muscle wasting and osteoporosis.использованная литература
[1] NATALIA LECIEJEWSKA . Sex-specific cytotoxicity of ostarine in cardiomyocytes[J]. Molecular and Cellular Endocrinology, 2023, 577: Article 112037. DOI:10.1016/j.mce.2023.112037.[2] HARJOT BEDI. Drug-Induced Liver Injury From Enobosarm (Ostarine), a Selective Androgen Receptor Modulator.[J]. ACG Case Reports Journal, 2021: e00518. DOI:10.14309/crj.0000000000000518.
[3] PJ R, D H, JC C, et al. Ostarine and Ligandrol Improve Muscle Tissue in an Ovariectomized Rat Model.[J]. Front Endocrinol (Lausanne), 2020, 11: 556581.
[4] JAMES T. DALTON. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial[J]. Journal of Cachexia, Sarcopenia and Muscle, 2011, 2 3: 153-161. DOI:10.1007/s13539-011-0034-6.
[5] ADRIAN S DOBS. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial.[J]. Lancet Oncology, 2013, 14 4: 335-345. DOI:10.1016/S1470-2045(13)70055-X.
[6] JEFFREY CRAWFORD. Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials).[J]. Current Oncology Reports, 2016, 18 6: 37. DOI:10.1007/s11912-016-0522-0.
[7] ALVARO MORALES. Diagnosis and management of testosterone deficiency syndrome in men: clinical practice guideline.[J]. Canadian Medical Association journal, 2015, 187 18: 1369-1377. DOI:10.1503/cmaj.150033.
[8] Watts D. Ostarine Reviews: shocking results & information about MK2866. SECEC. https://secec.org/ostarine-mk2866/. Accessed May 18, 2020.
Ostarine поставщик
| поставщик | телефон | страна | номенклатура продукции | благоприятные условия | |
|---|---|---|---|---|---|
| +8613363867578 | China | 151 | 58 | ||
| +8619521488211 | China | 2558 | 58 | ||
| +1-2135480471 +1-2135480471 |
China | 10473 | 58 | ||
| +8617653113209 | China | 3049 | 58 | ||
| +8613545065237 | China | 153 | 58 | ||
| +86-86-1913198-3935 +8617331935328 |
China | 970 | 58 | ||
| +86-16631818819 +86-17736933208 |
China | 9300 | 58 | ||
| +86-86-4001020630 +8619831957301 |
China | 1000 | 58 | ||
| +8613043004613 | China | 283 | 58 | ||
| +86-13335044410 +86-13335044410 |
China | 110 | 58 |